

Special Issue

Clinical Experience with Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment

Message from the Guest Editors

The therapeutically intended application of cold physical plasma in cancer patients is stepping upwards in the pyramid of evidence-based medicine (EBM). There is already a consensus among experts regarding the appropriate response to plasma in experimental settings such as cancer cell lines, cultivated human tumor cells, human tumor specimen freshly explanted from patients, animal model tumors, and animals with transplanted human tumor stem cells. Now, the next step and the main focus of this Special Issue of *Cancers* is the proof of concept through well-documented case reports and clinical pilot studies. There are already some studies on the way concerning clinical effectiveness, side effects, optimal application, and treatment period. If there is a manageable amount of tumor stem cells such as in precancerous lesions of skin and mucosa or in small tumors such as early basal cell carcinoma of the skin, plasma could become an approved clinical treatment option soon.

Guest Editors

Prof. Dr. Hans-Robert Metelmann

Department of Oral and Maxillofacial Surgery/Plastic Surgery,
Greifswald University Medicine, Greifswald, Germany

Dr. Christian Seebauer

Department of Oral and Maxillofacial Surgery/Plastic Surgery,
Greifswald University Medicine, Greifswald, Germany

Deadline for manuscript submissions

closed (20 June 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/63628

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)